DISCOVERY | CLINICAL DEVELOPMENT | |||||
---|---|---|---|---|---|---|
EXPLORATORY | LEAD OP | IND-ENABLING | PHASE 1 | PHASE 2 | PHASE 3 | |
PRIVILEGED CHEMOTYPE LIBRARY |
Bipolar Depression (Lead Program) | |||||
Treatment-Resistant Depression (TRD) | ||||||
Schizophrenia (Exscientia) | ||||||
Geriatric Psychosis (Exscientia) |
Existing drug classes are relatively ineffective for treating the 6 million adult Americans with bipolar disorder and maintenance. Our lead drug candidate, OAK-0011379, exhibits in vivo activity that will help predict efficacy as a rapid-acting and sustained antidepressant for people with bipolar disorder.
LEARN MOREThere have been no new mechanisms-of-action approved in the last 40 years for treating geriatric psychosis and schizophrenia, and existing drugs often produce severe side effects. OAK-0011799 optimizes dual targeted small molecules for a historic opportunity to develop superior classes of therapeutics for those suffering from these disorders.
LEARN MOREBlue Oak has received sustained funding from the National Institute of Mental Health (NIMH) to support drug discovery and clinical development.
For investment or partnership opportunities or to learn more about our clinical programs, contact our team today.
CONTACT US